Introduction
Hypertension is a major contributor to death and disability from heart and vascular diseases. The estimated number of years of life lost to hypertension-related diseases in 2010 included: ischemic heart disease 7.2 million; stroke 1.9 million; chronic kidney disease, other cardiovascular and circulatory, and hypertensive heart disease 2.2 million combined. 1 Treatment and control of hypertension reduce fatal and non-fatal cardiovascular events, especially when combined with effective hypercholesterolemia management. 2 Million Hearts estimated that level of success in all adults could prove challenging. Many clinical settings, e.g., federally
qualified health centers and rural clinics, have fewer resources and supports for quality improvement and provide care for a larger proportions of adults, including the uninsured, who typically have less favorable outcomes than Kaiser. 9, 10 This analysis of National Health and Nutrition Examination Survey 1999-2012 data was conducted to better understand trends and key variables impacting Healthy People 2020 goals for hypertension prevalence, treatment and control. More specifically, current status and trends in hypertension awareness, treatment, and control were assessed and modifiable factors that could facilitate progress toward Healthy People 2020 goals were identified.
Methods
The National Health and Nutrition Examination Surveys (NHANES) assess health and nutritional status of the U.S. civilian non-institutionalized population. Participants are selected using a multistage, probability sampling design. All adults provided written consent approved by the National Center for Health Statistics.
Participants included adults 18 years old in NHANES 1999-2012 with at least one recorded blood pressure (BP).
Race/Ethnicity was determined by self-report and separated into non-Hispanic white (white), non-Hispanic black (black), Hispanic ethnicity, and other.
Blood pressure (BP) was measured by trained professionals using sphygmomanometry and appropriately sized arm cuffs in volunteers after five minutes seated rest. The first BP was excluded in estimating mean systolic and diastolic values for individuals with more than one value as recommended in NHANES physician examination procedures manuals.
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Hypertension was defined by: systolic BP 140 and/or diastolic BP >90 mmHg and/or positive response to "Are you currently taking prescribed medication to lower your BP?"
Awareness of hypertension was defined by the percentage of adults with prevalent hypertension reporting a physician told them they had hypertension.
Treatment of hypertension was defined by the percentage of adults with prevalent hypertension reporting that they were taking prescription medication to lower BP.
Percentage of treated hypertension controlled was calculated as the number of adults on BP medications with values <140/<90 mmHg divided by the number of treated adults.
Hypertension control was defined as BP <140/<90 mmHg in all adults with hypertension including those with diabetes mellitus and chronic kidney disease. 18 Diabetes included: 19 (a) Diagnosed diabetes defined by positive response(s) to one or more questions, "Have you ever been told by a doctor that you have diabetes?", "Are you now taking insulin?", or "Are you now taking diabetic pills to lower your blood sugar?" (b)
Undiagnosed diabetes defined by fasting glucose 126 mg/dL and/or glycosylated hemoglobin (HbA1c) 6.5%.
Hypercholesterolemia was defined by non-HDL-cholesterol relative to Framingham 10-year coronary heart disease risk as previously described. 2 Non-HDL-cholesterol was used, since LDL-cholesterol values were missing on more than half of subjects and participants with and without values were different.
Hypercholesterolemia Treatment was determined by adults answering affirmatively to "Are you taking prescribed medication to lower your cholesterol?"
Chronic kidney disease (CKD) was defined as estimated glomerular filtration rate (eGFR) <60 mL/1.73 m 2 /min and/or urine albumin:creatinine >300 mg/g, i.e., values previously ncluding those with diabetes mellitus and chronic kidney disease.
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Diabetes included: 19 (a) Diagnosed diabetes defined by positive response(s) to one or mo more re reu ue uest st stio io ion n ns, "H "H "Ha ave you ever been told by a do do doc ct tor that you ha a ave v v d di i iab ab abet e es?", "Are you now a aki i ing n insulin?" ?" ", , o or r " " "Ar Ar A e e e yo yo ou u u n no now w w ta ta aki king ng g dia a ab betic c p pi ills s t to o o lo lo ow we wer r yo yo your selected to define a lower blood pressure target than <140/<90 mmHg. 20 Serum creatinine values were adjusted to account for methodological differences across surveys. 21 Cardiovascular disease included: (i) coronary heart disease (CHD) defined by positive response to three questions listed previously. 18 (ii) Stroke was defined by endorsement of "Has a doctor ever told you that you had a stroke?" 22 (iii) Congestive heart failure was defined by affirmative response to "Has a doctor ever told you that you had congestive heart failure?"
Medical visits were defined in response to "How many times did 3you receive health care
over the last year"? Answers were dichotomized into <2 vs. 2 visits annually.
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Cigarette smoker was defined if a patient answered "Every day" or "some days" to "Do you now smoke cigarettes?"
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Data analysis
SAS version 9.4 (Cary, NC) survey procedures were used for within survey analyses and appropriate weights accounting for unequal probabilities of selection, oversampling, and nonresponse were used. NHANES reporting guidelines were followed. The clinical epidemiology of hypertension was age-adjusted to the U.S. 2010 Census. In 2010, the proportion of adults aged 18 to 44 years, 45 to 64 years, and 65 years was 0.481, 0.348, and 0.171. 23 For age-adjusting hypertension awareness, treatment, and control across time, additional weights were calculated, since prevalent hypertension varies by age group. The proportion of adults in each age group that were hypertensive was multiplied by their respective year 2010 weight for all adults. Weights were then calculated by dividing the product for each age group by the sum of products for all three age groups in each survey. 5 
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For within survey between group comparisons at each of the three NHANES time period, RaoScott Chi-Square Tests were used to assess differences in distributions of categorical variables and Wald F-tests for differences in continuous variables. Pairwise comparisons between the three NHANES periods were conducted with t-tests of weighted means. Odds ratios and 95%
confidence intervals were calculated and statistical significance assumed when 95% confidence intervals do not cross the line of identity (1.0).
Results
The process for identifying 12,262 adults with hypertension in NHANES 1999-2012 is depicted in Figure 1 . Across time, adults with hypertension did not differ significantly by age, sex, race, healthcare insurance, or prevalent hypercholesterolemia, CVD, CKD or 10-yr CHD risk <10%
( Table 1 awareness and treatment were higher in the two older groups than adults <45 years. The proportion of treated adults controlled was higher at ages <45 and 45-64 than 65 years.
Hypertension control was greater among adults 45-64 than 18-44 years old.
Prevalent hypertension was higher in black than white and Hispanic adults (Figure 3) .
Hypertension awareness and treatment were higher in black than Hispanics adults. The proportion of treated adults controlled was higher in whites than blacks. Hypertension control did not differ significantly between the three race/ethnicity groups, although 95% confidence intervals were relatively wide, especially in Hispanic adults.
Data for the clinical epidemiology of hypertension in Figure 2 are provided in Supplemental Table 1 . Descriptive data for the three age groups shown in Figure 3 are provided in Supplemental Table 2 . P-values for between group within time period and within group between time periods are provided in Supplemental tables 2a and 2b, respectively.
Descriptive data for the white, black, and Hispanic groups in Figure 3 are provided in Results of the multivariable logistic regression analysis to identify variables associated with hypertension awareness, treatment and control are shown in Table 2 . Among modifiable variables, prevalent hypertension was greater with increasing body mass index, more frequent healthcare and in adults reporting treatment for cholesterol. Adults unaware of hypertension were less likely to have more frequent healthcare, higher body mass indices, and to affirm treatment De De esc sc s ri ri ript pt ptiv ive e e da d data ta fo or or t th h he w whi h te te te, , bl bl blac ac ack, k k, a a and nd d H H Hi ispa pa pani ni ic gr gr g ou ou oups ps ps i i in n Fi Fi F g gu gure re re 3 3 ar re re p p pro ro r vi vi v de de ded d d in n Supplement tal al al T T Tab ab able le l 3 3 3. . P--va va valu lu l es es es f for or or w w wit it i hi hi hin n n an an and d d be be betw tw wee e en n n gr gr grou ou oup p p co c c mp mp mpar ar aris is ison on ons s ar ar are e e pr pr prov ov ovided in for hypercholesterolemia. Adults with untreated hypertension were less likely to have more frequent healthcare, to be obese, insured, and to affirm treatment for hypercholesterolemia. The ratio of treated patients controlled was higher in adults with more frequent healthcare, with healthcare insurance, and who reported treatment for hypercholesterolemia in the prior month.
Supplemental
Hypertension control was greater in subjects with more frequent care, higher body mass indices, healthcare insurance, and those reporting hypercholesterolemia treatment in the prior month.
Discussion
The main objective of this NHANES 1999 to 2012 analysis was to assess current status and trends in the clinical epidemiology of hypertension relative to Healthy People 2020 goals. Healthy People 2020 defined prevalent hypertension as treatment for hypertension and/or BP 140/ 90 mmHg. 7 Thus, in addition to decreasing incident hypertension, prevalent hypertension can be reduced by lifestyle changes that (1) decrease BP to <140/<90 in untreated adults (2) control BP to <140/<90 without medications in previously treated adults.
Prospective observational and interventional studies document that body mass index and changes in body mass index are strongly related to incident and prevalent hypertension across the adult age span; [24] [25] [26] [27] and, this was the only modifiable, lifestyle-related factor included in our rends in the clinical epidemiology of hypertension relative to Healthy People 20 020 20 20 goa oa oals ls s. Table 2) . While health insurance was not independently related to awareness, insurance increases healthcare utilization and risk factor awareness. 30, 31 Growth of accountable care organizations should also raise hypertension screening and awareness. . Hyp yper er e t t tens ns sio ion n n aw aw awar ar aren ene es ess s s is s s l lo owe e er i i in adu du dults w wh who o a ar re e ma ma male le a and nd n inf nf fre re equ quen en entl tl tly y u us use e e he heal al alth th hca ca c re re ( ( (Ta Ta T bl bl le 2 2). ). W W Whi hile l h h hea a alt lt lth h h i in insu su ura ra ranc nc nce e w wa was s s n no ot i ind nd dep ep epen n nde de d nt nt n ly ly ly r re e elat at ted ed d t t to o aw aw war ar aren ene e ess s, s, nsurance incr cr rea ea ease se es s s he he heal al lthca ca care re re u u uti ti tili liz z zat a a io io on n an an and d d ri ri isk sk k f f fac ac acto tor r r aw aw awar ar a en en enes e e s. s. s. 30 30, 30,31 31 31 G G Gro ro rowt wt th h h of of of a a acc cc c ountable patients who are aware and treated, the proportion of treated adults who must be controlled to attain the BP control goal of 61.2% declines and becomes more feasible. While 87.1% of adults with hypertension were controlled during 2011 in a large insured, managed-care organization, 8 this substantially exceeds levels observed among treated patients in the U.S. (Figure 2 ). Less evident is that higher control rates require BP control on a greater percent of visits, which necessitates mean systolic and diastolic blood pressure and/or inter-visit BP variability below current levels.
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The main analysis for this report centered on hypertension control at <140/<90 mmHg for all adults irrespective of age and comorbid health conditions. in the U.S. adult population declines from 88.1% to 78.5%, which is in the range obtained by a growing number of practice settings. 37 In multivariable analysis, modifiable factors independently associated with hypertension control in treated adults included health insurance, 2 annual healthcare visits, and hypercholesterolemia treatment.
Previous reports document that health insurance is associated with hypertension control goal for adults 60 years was recently established as <150/<90 mmHg by the Co omm mm mmit t tte te ee e e appointed to JNC 8, 35 which would increase the percentage of treated patients controlled and ov ver er eral al all l l co co ont nt ntro ro ol. 18 18 8 H H Ho owever this recommendation n n i is a at variance wit it th h ot the he her r r guidelines and expert opin n nio i n, 36 whi ich ch ch c con onti ti t nu u ue e to to to r r re ec ecom om mm me mend nd d a B B BP P P go oa al l of f < <14 140/ 0/ 0 <9 <9 < 0 0 0 e ex xce cep p pt f for or a ad du dult lts s s 80 80 80 ye ea ears rs s o o old fo or r r wh wh whom om o t t the he he B BP P P g go goal al l o of f <1 < 50 50 5 /< /< /<90 90 90 i is s re re r co co comm mm mmen en e d de ded d. d
The He He Heal al a th th hy y y Pe Pe eop op o le le e 2 2 202 02 020 0 0 go go goal a a o o of f co co cont nt ntro ro roll ll lin in ing g g hy hype pe pert rt rten en ensi si sion on o i i in n n 61 61 61.2 .2 .2% % % of of f a a all ll ll a a adu du dults requires s s y y y among adults treated for hypertension. [30] [31] [32] The link between hypercholesterolemia treatment, mainly statins, and hypertension control is largely indirect. In a meta-analysis of 40 randomized placebo-controlled studies, patients randomized to statins had a 2.6 mm Hg reduction in systolic BP compared to the placebo group. 38 In the Anglo-Scandinavian Cardiac Outcomes Trials (ASCOT), hypertensive patients randomized to atorvastatin had a significantly lower risk of treatment resistant hypertension than patients randomized to placebo. 39 These studies were not designed to assess statin effects on BP or treatment resistance and do not constitute compelling evidence to recommend statins for BP reduction. However, if statins lower BP and reduce treatment resistant hypertension as suggested by randomized, placebo-controlled trials, 38,39 then implementing the 2013 Cholesterol Guidelines, which increase the number of hypertensive adults eligible for statin therapy by a net of ~7 million, 40 could improve hypertension control.
Race/ethnicity disparities in hypertension control persist when controlling for confounding factors ( Table 2) . Hypertension control was lower in black than white adults with hypertension, although blacks were more likely to be aware of and treated for hypertension than whites. Thus, the primary factor contributing to less hypertension control in black than white adults is the lower proportion of treated individuals attaining target blood pressure ( Table 2) .
Greater attention in black adults to modifiable factors independently associated with the proportion of treated adults controlled including 2 healthcare visits/year and health insurance could improve equity in hypertension control. Moreover, in 1999-2012, blacks were less likely to report cholesterol treatment than whites, despite greater 10-year CHD risk (Supplemental Tables 3, 3a) . Thus, implementing current guideline-based statin therapy may improve equity in hypertension control.
Hypertension control was also lower in Hispanic than white adults when accounting for mplementing the 2013 Cholesterol Guidelines, which increase the number of hyp yp per er rte tens ns n iv iv ive e e adults eligible for statin therapy by a net of ~7 million, 40 could improve hypertension control.
Ra Ra Race ce c /e / /eth hni ni nic ci city disparities in hypertension n n co o ontrol persist w w when n co co cont n rolling for co on nf nfou o nding fa fact ct to or rs ( ( (Ta Ta Tabl bl ble e e 2 2 2). ) ). H Hyp yp yper ert t ten n nsio on n c con nt tro ol wa wa was s lo lo ow we wer r in in b bla lack ck c tha ha an n wh whit it ite e ad ad dul ults ts ts w w wit t th h hy hype pe pert rt rten en e si sion on on, , al alt th tho ou ough gh gh b b bla lack k ks s s we we were re re m mo o ore re e l l lik ik ikel l ly y y to to o b b be aw aw awar ar are e of of of a and nd nd t t tre re r a a ate ed ed f f for or o h h hyp yp yper er erten n nsi io ion n t th than an a whites. Thus s, , th th the e pr pr prim im imar ar ary y fa fa fact ct ctor r r c c con on ntr t ib ib but ut utin in ing g g to to to l l les es ess s hy hy h pe pe pert rt rten en ensi si sion on on r r co co cont nt ntro ro rol l l in in in b bla la lack ck ck t t tha ha han n white potential confounders ( Table 2) . Hispanic adults were less likely than white adults to receive treatment for hypertension and less likely to be controlled when treated. Variables independently associated with both untreated hypertension and proportion of treated adults controlled included infrequent healthcare and lack of health insurance. With regard to the importance of health insurance, in a previous NHANES report of adults with multiple risk factors, Hispanics <65 years old were roughly three times more likely to be uninsured than whites in the age group (41% vs. 13%). 41 In particular, Hispanics <65 years were less likely to be treated for hypertension and less likely to be controlled when treated, which is consistent with the current report. Disparities in multiple risk factor control between whites and Hispanics <65 years old
were not evident at ages 65 years. While this analysis did not focus on age by race/ethnicity subgroups, greater attention to these modifiable variables, especially in Hispanic adults <65 years old, could improve equity in hypertension control.
In this report, adults <45 years were less likely to be aware of and treated for hypertension than older adults, but more likely to be controlled when treated. Our previous NHANES analyses indicate that infrequent healthcare, especially among men <45 years old, is a major contributor to undiagnosed and untreated hypertension in this age group.
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Limitations include relatively small cross-sectional samples of the U.S. population.
Confidence intervals are often wide, which limits power for detecting clinically significant differences in the epidemiology of hypertension. Blood pressure was measured by trained professionals using a standardized protocol. Yet, hypertension status among untreated adults and control among treated adults were based on a single evaluation. Moreover, significant associations between independent and dependent variables in multivariable logistic regression analyses do not establish causal relationships.
were not evident at ages 65 years. While this analysis did not focus on age by ra ra ace e e/ /eth th thni ni nici ci city ty ty ubgroups, greater attention to these modifiable variables, especially in Hispanic adults <65 ye year ar ars s ol ol old d, d, c c cou ou uld d i i im mp mprove equity in hypertension n c c con n ntrol.
In this s re repo po port t, ad adul ul ults ts ts < < <45 4 45 y y yea ea ears rs w w were le e ess lik ike ely y to to o b be e e a aw awa a are e e of of f a a and d t tr re rea at ated ed f f for or r hy hype pe pert rt rten en e si sion on on t tha han n ol old de er r ad adul lts ts t , bu bu but t t mo mo more re re l l lik ik ikel ely y y to to b be e c co cont nt ntro ro roll lled ed ed w w whe he hen n n t tr tre ea ate ted d. d O O Our ur r p p prev v vio ou ous s NHANES ana na aly ly lyse se es s s in in i di di dica c te te te t t tha ha h t t t in in infr fr freq eq que ue u nt nt n h h hea ea ealt lthc hc hcar ar are, e e e esp sp spec ec ecia a all ll lly y y a a amo mo mong ng ng m m men en e < < <45 45 45 y y yea ea e rs old, is a a a
In summary, our analysis shows that age-adjusted prevalent hypertension has remained at roughly 30% of adults from 1999-2012, which is above the Healthy People 2020 goal of 26.9%.
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Supplemental Materials
Supplemental Table 1 : Data for mean and 95% confidence intervals are provided for the clinical epidemiology of hypertension displayed in Figure 2 .
Supplemental Table 2 . Descriptive data are provided for adults by age group.
Supplemental Table 2a . P-values are provided for differences between age groups within each NHANES time period Supplemental Table 2b . P-values are provided for differences within age groups between NHANES time periods.
Supplemental Table 3 . Descriptive data are provided for adults by race/ethnicity subgroup.
Supplemental Table 3a . P-values are provided for differences between race/ethnicity groups within each NHANES time period.
Supplemental Table 3b . P-values are provided for differences within race/ethnicity group between NHANES time periods. 
